MEREO BIOPHARMA GROUP PLC (MREO) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$7.03M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$8.77M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$10.02M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$10.50M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$7.03M | (m) | (m) | (m) | $0.00* | -$6.04M* | (m) | $1.81M | (m) | $0.00 |
| 2026-03-31 | Reported | (m) | -$8.77M | (m) | (m) | (m) | $0.00 | -$4.31M | (m) | $4.75M | (m) | $0.00 |
| 2025-09-30 | Reported | (m) | -$10.02M | (m) | (m) | (m) | $0.00* | -$7.31M* | (m) | $4.27M | (m) | $0.00 |
| 2025-06-30 | Reported | (m) | -$10.50M | (m) | (m) | (m) | $0.00* | -$7.65M* | (m) | $5.37M | (m) | $0.00 |
| 2025-03-31 | Reported | (m) | -$11.20M | (m) | (m) | (m) | $20.00K | -$8.33M | (m) | $3.93M | (m) | $0.00 |
| 2024-09-30 | Reported | (m) | -$9.37M | (m) | (m) | (m) | $0.00* | -$7.52M* | (m) | $3.17M | (m) | $0.00 |
| 2024-06-30 | Reported | (m) | -$12.81M | (m) | (m) | (m) | $0.00* | -$7.90M* | (m) | $4.95M | (m) | $0.00 |
| 2024-03-31 | Reported | (m) | -$9.90M | (m) | (m) | (m) | $0.00 | -$7.99M | (m) | $3.99M | (m) | $0.00 |
| 2023-09-30 | Reported | (m) | -$9.07M | (m) | (m) | (m) | (m) | $2.66M* | (m) | $3.59M | (m) | $0.00 |
| 2023-06-30 | Reported | (m) | -$811.00K | (m) | (m) | (m) | (m) | -$7.75M* | (m) | $3.71M | (m) | $0.00 |
| 2023-03-31 | Reported | (m) | -$11.41M | (m) | (m) | (m) | (m) | -$9.25M | (m) | $5.31M | (m) | $0.00 |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$40.11M | (m) | (m) | (m) | $20.00K | -$30.97M | (m) | $17.77M | (m) | $0.00 |
| 2024-12-31 | Reported | (m) | -$47.36M | (m) | (m) | (m) | $0.00 | -$32.83M | (m) | $20.93M | (m) | $0.00 |
| 2023-12-31 | Reported | (m) | -$28.42M | (m) | (m) | (m) | $0.00 | -$21.13M | (m) | $17.42M | (m) | -$532.00K |
| 2022-12-31 | Reported | (m) | -$54.43M | (m) | (m) | (m) | $13.00K | -$48.82M | (m) | $29.46M | (m) | -$718.00K |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |